(-0.05%) 5 476.00 points
(-0.09%) 38 784 points
(-0.02%) 19 918 points
(0.22%) $80.51
(1.29%) $2.82
(0.24%) $2 334.50
(-0.16%) $29.35
(-0.21%) $968.90
(0.01%) $0.932
(-0.16%) $10.64
(0.06%) $0.788
(-1.86%) $86.81
2 days till quarter result
(bmo 2024-06-20)
Expected move: +/- 12.17%
Live Chart Being Loaded With Signals
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe...
Stats | |
---|---|
Šios dienos apimtis | 248 434 |
Vidutinė apimtis | 681 761 |
Rinkos kapitalizacija | 102.63M |
EPS | €-1.350 ( Q4 | 2024-03-28 ) |
Kita pelno data | ( €-1.690 ) 2024-06-20 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E |
-1.000 (Sector) 42.63 (Industry) 24.32 |
ATR14 | €0.0230 (0.34%) |
Tūris Koreliacija
Affimed NV Koreliacija
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
BOTT | -0.917 |
OPTZ | -0.887 |
GECCI | -0.859 |
MTEN | -0.844 |
CCSB | -0.838 |
AILEW | -0.804 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Affimed NV Koreliacija - Valiuta/Žaliavos
Affimed NV Finansinės ataskaitos
Annual | 2023 |
Pajamos: | €8.28M |
Bruto pelnas: | €8.28M (100.00 %) |
EPS: | €-7.09 |
FY | 2023 |
Pajamos: | €8.28M |
Bruto pelnas: | €8.28M (100.00 %) |
EPS: | €-7.09 |
FY | 2022 |
Pajamos: | €41.35M |
Bruto pelnas: | €41.35M (100.00 %) |
EPS: | €-0.600 |
FY | 2021 |
Pajamos: | €40.37M |
Bruto pelnas: | €0.00 (0.00 %) |
EPS: | €-0.480 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Affimed NV
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.